A self-illuminating nanoparticle for inflammation imaging and cancer therapy
Author(s) -
Xiaoqiu Xu,
Huijie An,
Dinglin Zhang,
Hui Tao,
Y. X. Dou,
Xiaohui Li,
Jun Huang,
Jianxiang Zhang
Publication year - 2019
Publication title -
science advances
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.928
H-Index - 146
ISSN - 2375-2548
DOI - 10.1126/sciadv.aat2953
Subject(s) - photodynamic therapy , singlet oxygen , in vivo , nanomedicine , biocompatibility , tumor microenvironment , photosensitizer , bioluminescence imaging , preclinical imaging , fluorescence lifetime imaging microscopy , nanotechnology , reactive oxygen species , materials science , nanoparticle , cancer , biophysics , chemistry , medicine , fluorescence , photochemistry , transfection , oxygen , biochemistry , biology , microbiology and biotechnology , quantum mechanics , metallurgy , physics , luciferase , organic chemistry , gene
Nanoparticles have been extensively used for inflammation imaging and photodynamic therapy of cancer. However, the major translational barriers to most nanoparticle-based imaging and therapy applications are the limited depth of tissue penetration, inevitable requirement of external irradiation, and poor biocompatibility of the nanoparticles. To overcome these critical limitations, we synthesized a sensitive, specific, biodegradable luminescent nanoparticle that is self-assembled from an amphiphilic polymeric conjugate with a luminescent donor (luminol) and a fluorescent acceptor [chlorin e6 (Ce6)] for in vivo luminescence imaging and photodynamic therapy in deep tissues. Mechanistically, reactive oxygen species (ROS) and myeloperoxidase generated in inflammatory sites or the tumor microenvironment trigger bioluminescence resonance energy transfer and the production of singlet oxygen (O) from the nanoparticle, enabling in vivo imaging and cancer therapy, respectively. This self-illuminating nanoparticle shows an excellent in vivo imaging capability with suitable tissue penetration and resolution in diverse animal models of inflammation. It is also proven to be a selective, potent, and safe antitumor nanomedicine that specifically kills cancer cells via in situ O produced in the tumor microenvironment, which contains a high level of ROS.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom